Top Doctor Top Doctor
The Top Doctor award is a peer-nominated award for providers who give exceptional care.

William P. Harris, MD

Seattle Cancer Care Alliance
Associate Professor, Division of Oncology
University of Washington School of Medicine
UW Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“I get to know my patients well. It’s an important part of guiding them through some very big and complicated decisions.”
— Dr. Harris
What experiences have informed your approach to oncology?

It was always my plan to work in cancer care, but I wanted to have broader medical training first, so I studied internal medicine before pursuing oncology. This background has proven valuable for helping me understand a patient’s entire medical history and manage the full scope of the difficult problems they face as part of a cancer diagnosis. Oncology is a unique specialty; I feel that we, as cancer physicians, are positioned to practice a delicate balance of the art and science of medicine. 

What do you want patients to know about working with you?

I believe in designing a treatment plan based upon the specifics of your unique case: the biology of your disease, your lifestyle preferences, how aggressively you want to approach the cancer and the risks you’re prepared to take to get the best results. I get to know my patients well. It’s an important part of guiding them through some very big and complicated decisions. Sometimes those decisions involve whether to participate in clinical trials, which provide access to new, promising therapeutic agents. Cancer therapy has come a long way, but there is still room for improvement. Trials can offer patients the latest advancements in care — and raise the bar for what will be the next standard of care. 

Provider background

Specialty: Medical Oncology

Gastrointestinal cancers

I am a board-certified oncologist who specializes in treating gastrointestinal cancers. These malignancies can affect the liver, bile ducts, gallbladder, pancreas, colon, rectum, anus, stomach and esophagus. I am a consultant for the Liver Tumor Clinic at UWMC and the SCCA’s multidisciplinary Pancreatic Cancer Specialty Clinic. I also serve as a moderator for UW 's Gastrointestinal Malignancy Tumor Board. 

In addition to providing clinical care, I also design and conduct clinical trials. My research focuses on new targeted therapies, immunotherapies, novel drug combinations and other experimental therapies for patients with liver and biliary-tract cancers. Other areas of interest include analyzing data relating to treatment outcomes for patients with GI cancers and identifying new treatments for fibrolamellar hepatocellular carcinoma, a rare liver cancer that affects children and young adults.

Diseases treated

Education, experience and certifications
Undergraduate Degree
Brown University
Medical Degree
Columbia University
University of Washington School of Medicine, General Internal Medicine
University of Minnesota, Pathology ; University of Washington School of Medicine, Medical Oncology
Board Certification
Medical Oncology, 2010, American Board of Internal Medicine
Internship, University of Washington
Seattle magazine's 2021 Top Doctors Award

Dr. Harris has been recognized as a Top Doctor in this peer-nominated award multiple years in a row.


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Complete title
An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors
Study ID:
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Complete title
An Open-Label Expanded Access Program OfFutibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Study ID:
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Complete title
A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.


SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Dr. Harris on IMbrave150 Results With Atezolizumab/Bevacizumab in HCC

SCCA’s William Harris, MD spoke with OncLive about updated phase 3 data from IMbrave150 study in hepatocellular carcinoma.

Dr. Harris on the Adoption of Immunotherapy in Advanced HCC

SCCA’s Dr. William P. Harris discussed the adoption of immunotherapy in advanced hepatocellular carcinoma.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers